Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Piccart, M.
Ruiz Borrego, M.
Duhoux, F.
Arkenau, H-T.
Doger de Speville, B.
Wildiers, H.
Campone, M.
Tosi, D.
Garcia-Corbacho, J.
Jimenez, B.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
